Premium
Efficacy of bortezomib, lenalidomide and dexamethasone ( VRD ) in secondary plasma cell leukaemia
Author(s) -
Gozzetti Alessandro,
Musto Pellegrino,
Defina Marzia,
D'Auria Fiorella,
Papini Giulia,
Steduto Teodora,
D'Arena Giovanni,
Bocchia Monica
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2012.09029.x
Subject(s) - lenalidomide , medicine , bortezomib , plasmacytosis , multiple myeloma , plasma cell leukemia , gastroenterology , dexamethasone , immunofixation , surgery , immunology , monoclonal , antibody , monoclonal antibody
Plasma cell leukaemia (PCL) is characterized by circulating\udplasma cells >2 9 109/l in peripheral blood and/or a peripheral\udblood plasmacytosis >20%. Primary PCL (pPCL) is\uddefined as a de novo appearance of disease, while secondary\udPCL (sPCL) corresponds to the leukaemic transformation of\uda previously diagnosed multiple myeloma (MM) (Albarracin\ud& Fonseca, 2011). sPCL still remains an exceedingly resistant\uddisease with median survivals of 2 months (Tiedemann et al,\ud2008; Musto et al, 2011a; Pagano et al, 2011). Lenalidomide\udhas been reported to have some activity’ in sPCL although it\udis short-lived (Benson & Smith, 2007; Musto et al, 2008),\udwhile better results have been described when this drug is\udused as first line therapy in pPCL (Musto et al, 2011b). Bortezomib\udhas been investigated with promising results as single\udagent or in combination both in pPCL and sPCL